# Twentyeight-Seven

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/twentyeight-seven

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.twentyeight-seven.com
- Total disclosed funding: $40M
- Latest round: Series A (May 9, 2019)
- Investors on record: 8

## About

Twentyeight-Seven, Inc. is focused on creating innovative small-molecule therapeutics that target dysregulated nucleic acid processes, aiming to restore cellular function and combat serious diseases like cancer and autoimmune disorders.Founded in 2016, Twentyeight-Seven, Inc. is headquartered in Watertown, US. The company specializes in developing therapeutics that address RNA and DNA processes. In May 2019, they raised USD 15.00 mn in Series A funding led by Sofinnova Partners, with participation from OUP (Osage University Partners). The total amount raised in this funding round aligns with the total raised since inception, amounting to USD 15.00 mn.Twentyeight-Seven, Inc. develops small-molecule therapeutics aimed at addressing dysregulated nucleic acid processes such as RNA and DNA. Their products target cellular mechanisms that control homeostasis, metabolism, differentiation, and responses to stimuli, focusing on serious diseases including cancer and autoimmune disorders. By aiming to influence multiple oncogenic pathways, their therapeutics seek to overcome limitations associated with traditional therapies that typically target single pathways. They cater to healthcare providers, pharmaceutical partners, and patients, particularly in the United States and Europe.The revenue model for Twentyeight-Seven, Inc. is centered on the development and commercialization of their therapeutic products. Revenue is likely generated through partnerships with pharmaceutical firms for clinical trials and distribution agreements, along with potential direct sales to healthcare providers upon product launch. While specific pricing structures remain undisclosed, the focus on small-molecule drugs suggests alignment with industry-standard pricing models. Their flagship products concentrate on addressing cancer and autoimmune diseases through innovative nucleic acid regulation, ultimately enhancing patient outcomes.Following the recent Series A funding round in May 2019, which raised USD 15.00 mn, Twentyeight-Seven, Inc. plans to utilize these funds to advance the development of their therapeutics targeting dysregulated nucleic acids. The company is focusing on launching new products designed to address complex diseases and exploring expansion into additional markets, including further penetration into the United States and European healthcare sectors. Details on specific product launch timelines and market entry strategies are to be determined as they progress.

## Funding rounds

- Series A, May 9, 2019, $15M — Sofinnova Partners, OUP (Osage University Partners)
- Series A, Sep 6, 2018, $25M — Novartis Venture Fund, Astellas Venture Management, Johnson & Johnson Innovation, MPM BioImpact, Longwood Fund, Vertex Ventures HC

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series A
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A